
Opinion|Videos|January 20, 2025
A 70-Year-Old Man with Early Relapsed/Refractory Multiple Myeloma
Author(s)Amrita Krishnan, MD
The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please share your initial impressions of the patient case.
- A decision to switch therapy was made. What regimen are you most likely to recommend for this patient?
- How do you set a patient up for the best success in early-stage R/R MM?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































